Actively Recruiting
Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy
Led by Xinjiang Medical University · Updated on 2025-04-15
570
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
Sponsors
X
Xinjiang Medical University
Lead Sponsor
F
First Affiliated Hospital of Xinjiang Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.
CONDITIONS
Official Title
Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years
- Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society
- Unilateral primary aldosteronism confirmed by adrenal vein sampling or PET-CT according to international guidelines
- Patients and their family members have signed informed consent and agreed to participate in the study
You will not qualify if you...
- History of severe hypersensitivity to contrast media
- Severe liver disease complications such as thrombocytopenia or esophageal varices rupture bleeding
- Renal insufficiency (serum creatinine > 176 mmol/L or estimated glomerular filtration rate < 1.73 m2)
- Other secondary hypertension conditions like pheochromocytoma, hypercortisolism, renal vascular hypertension, renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension, pregnancy hypertension
- Genetic diseases such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)
- Stroke, myocardial infarction, or stent implantation within the past 3 months
- Serious diseases including grade IV heart dysfunction, acute infections, autoimmune diseases, malignant tumors
- Participation in other clinical trials within the past 3 months
- Pregnant, breastfeeding, or planning pregnancy
- Known allergy to alcohol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 630000
Actively Recruiting
Research Team
X
Xiang Xie, PhD
CONTACT
C
Changjiang Deng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here